And yes, Valeant's stock is getting hammered (VRX)

pulse

March 14, 2017 1:57 PM

A day after the company's biggest cheerleader on Wall Street sold his stake, Valeant is feeling the pain

Valeant's stock is down around 9%, sliding on the news that investor Bill Ackman's hedge fund, Pershing Square, is unloading its entire stake in the company.

This ends a three-year involvement with the company for Ackman. During that time, Valeant's stock price fell from a high of about $279 in the summer of 2015, to where it sits under $11 today.

The company became the subject of several federal investigations, including one involving a secret pharmacy that it used to operate which is now be accused of insurance fraud.

And it was pressured to hire a new CEO while its executives were repeatedly called to Washington for Congressional hearings to answer for drug price increases.

It was quite a ride.

pulse